S&P 500 7,637.76 +1.14%
Nasdaq 26,418.30 +1.69%
S&P/TSX 35,874.26 +1.08%
Apple 337.00 +1.38%
Nvidia 219.34 +2.54%
Microsoft 497.75 +1.52%
Shopify 180.01 −0.97%
Royal Bank 284.93 +0.66%
CAD/USD 0.7155 +0.09%
CLOSED · 00:05 ET
Market ClerkRecap
Fri Sep 18 · markets closed3 signals on Sep 17300 insider buys this week · $205.1MCIRO short report next: Sep 29The week ahead
PM
INSIDER · HALO · HALOZYME THERAPEUTICS, INC. · DIRECTOR

Posard Matthew L.

Every open-market transaction filed under this name, Sep 16 to Sep 16.

Filings
4
0 buys · 4 sells
Bought
open market, at cost
Sold
$2M
includes scheduled sales
Buys since
no current price on file

Filings

SEC FORM 4 · OPEN MARKET
TradedTickerCompanyRoleTypeSharesPriceValueSince
Sep 16HALOHALOZYME THERAPEUTICS, INC.DirectorSell4,000$108.99$436K−2.5%
Sep 16HALOHALOZYME THERAPEUTICS, INC.DirectorSell8,896$108.04$961K−1.7%
Sep 16HALOHALOZYME THERAPEUTICS, INC.DirectorSell3,000$106.83$320K−0.5%
Sep 16HALOHALOZYME THERAPEUTICS, INC.DirectorSell3,100$106.13$329K+0.1%

"Since" is the stock's move from the filed price to the latest quote on file, not a scored call. Open-market purchases and sales only; option exercises and grants are excluded.